Drug Profile

EMX 001

Alternative Names: DengueTcP; DengueTcP^TM; EMX-001; Flavivirus vaccine - Gylden Pharma; naNO-Dengue; PepGNP-Dengue; Universal Flavivirus vaccine

Latest Information Update: 22 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Emergex Vaccines
Developer Gylden Pharma
Class Dengue vaccines; Peptide vaccines; Synthetic vaccines; Viral vaccines; Zika virus vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

22 Aug 2025 Phase I development for Dengue (Prevention) is ongoing in Switzerland (Transdermal) (Gylden Pharma pipeline 2025)
22 Aug 2025 Preclinical trials in Zika virus infection (Prevention) in United Kingdom (Transdermal) (Glyden Pharma pipeline, August 2025)
24 Feb 2025 Gylden Pharma plans to initiate enrollment in a phase II trial for dangue (Prevention) in Brazil in second quarter of 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com